-- 据《金融时报》周二报道，阿布扎比国家石油公司（ABU Dhabi National Oil）将向美国天然气价值链投资“数百亿美元”，目前正在评估29项潜在交易。报道援引该公司投资机构XRG首席投资官纳米尔·西迪基（Nameer Siddiqui）的话称。 西迪基在接受该通讯社采访时表示，在美伊冲突扰乱能源市场后，XRG的目标是实现大宗商品投资多元化，同时把握全球及美国液化天然气需求不断增长的机遇。 据报道，西迪基表示，该公司正在评估控股交易、钻井合资企业和少数股权投资等方案。 XRG计划渗透整个天然气价值链，项目涵盖天然气开采、管道建设、加工厂和液化设施。开发项目还可能包括再气化设施和通往目的地国家的管道。 西迪基表示，该公司希望在美国能源市场进行“大胆”投资。 与其他未能成功在美国建设一体化液化天然气项目的公司相比，XRG将凭借其单一股东的雄厚实力和长远眼光而占据优势。 据《金融时报》报道，Rapidan Energy全球天然气总监Alex Munton表示，由于银行通常出于对供应过剩的担忧而避开该领域，因此资金雄厚的中东投资者在开拓美国天然气市场方面具有优势。 然而，Munton表示，在俄罗斯入侵乌克兰后，美国液化天然气需求激增，加上特朗普政府的大力支持，XRG必须找到进入“已然成熟的市场”的途径。 XRG持有位于德克萨斯州的Rio Grande液化天然气工厂的股份。 除美国外，该公司还在埃及、莫桑比克和阿塞拜疆收购了资产。据新闻机构报道，该公司也对澳大利亚的液化天然气项目感兴趣，尽管它已于2025年9月撤回了对澳大利亚油气公司桑托斯（Santos）190亿美元的收购要约。 迄今为止，XRG最大的几笔交易都集中在化工行业，此前该公司与奥地利OMV合并成立了博禄国际（Borouge International），并以147亿欧元（约合171.9亿美元）的价格收购了德国科思创（Covestro）。 与此同时，据《金融时报》援引XRG能源解决方案总裁米歇尔·菲奥伦蒂诺（Michele Fiorentino）的话称，由于需求低迷，该公司将停止对低碳能源的投资，转而专注于天然气项目。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源，但可能包含传闻和推测。准确性无法保证。）
Related Articles
Sectors
Sector Update: Tech Stocks Fall Late Afternoon
Tech stocks fell late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) dropping 1.5% and the State Street SPDR S&P Semiconductor ETF (XSD) slumping 4.4%.The Philadelphia Semiconductor index shed 3.3%.In corporate news, OpenAI recently missed its own targets for new users and revenue, the Wall Street Journal reported late Monday, citing people familiar with the matter. Tech bellwether Nvidia (NVDA) fell 1.2%, Broadcom (AVGO) dropped 4.2%, Advanced Micro Devices (AMD) shed 3.1%, Oracle (ORCL) lost 3.6%, and Intel (INTC) declined 1.4%.Lam Research (LRCX), Applied Materials (AMAT) and KLA (KLAC) were among the chip equipment companies believed to have received a letter last week from the US Department of Commerce ordering them to halt certain tool shipments to China's second-largest chipmaker Hua Hong, Reuters reported. Lam declined 3%, Applied Materials dropped 5.1%, and KLA shed 4.1%.Amazon.com (AMZN) plans to make OpenAI's artificial intelligence models available to its customers after Microsoft (MSFT) relinquished its exclusive rights to resell the ChatGPT maker's products, Bloomberg reported Tuesday, citing Amazon Web Services CEO Matt Garman in a Bloomberg Television interview. Amazon shares were down 0.6%, and Microsoft rose 0.6%.Spotify Technology (SPOT) reported stronger-than-expected Q1 profit, but its premium subscriber growth and outlook disappointed investors. The stock fell 12%.
$AMAT$AMD$AMZN$AVGO$INTC$KLAC$LRCX$MSFT$NVDA$ORCL$SPOT
Research
Research Alert: Paccar: Q1 Eps Match Expectations; Class-8 Outlook Reiterated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PCAR's Q1 results matched consensus with operating EPS of $1.15 vs. $0.96 in the prior year, supported by the absence of litigation charges that impacted Q1 2025. New truck deliveries fell 7K units to 33.1K globally, with North American Class-8 shipments declining while Europe showed strength. The Parts business managed positive expansion despite truck sales softness, benefiting from strategic investments in distribution infrastructure. Management maintained an upbeat tone on customer demand trends, though their North American outlook for retail Class-8 truck sales remained unchanged from Q4. PCAR generated healthy operating cash flow of $972M vs. $910M and maintained a strong balance sheet, in our view. Management projected full-year capex of ~$750M and R&D expenses of ~$475M for next-generation powertrains. We see the unchanged shipment projections as a signal that management is not entirely confident an inflection is occurring stronger than previously anticipated.
$PCAR
Australia
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) shares fell 48% Tuesday after the company reported preliminary phase 1 dose-escalation data for its experimental ERAS-0015 in patients with RAS-mutant solid tumors, including colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma.The preliminary data, from ongoing trials in the US and China, suggest ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens, the company said.The therapy was generally "well tolerated," with no dose-limiting toxicities or treatment discontinuations due to adverse events, according to a statement.Erasca said it selected 24 mg and 32 mg once daily as recommended doses for further study and said the drug showed "promising clinical potential" for combination use with panitumumab.In a regulatory filing, the company said a patient, who was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma, had died. The company said grade 3 treatment-related adverse events of pneumonitis progressed to grade 5 following withdrawal of supportive care per patient decision.Price: $9.96, Change: $-9.20, Percent Change: -48.02%
$ERAS